Christoph B Olivier’s Team Explores Platelet Reactivity and Fibrin Clot-Strength in AF
Jan Hartmann, Chief Medical Officer at Haemonetics, reposted from Haemonetics on LinkedIn:
”Encouraging progress in personalized cardiovascular care.
A recent paper from Christoph B Olivier’s team at my alma mater, The University of Freiburg, explores “Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention”.
Their findings suggest that combined high platelet reactivity and increased platelet–fibrin clot strength after the PCI may elevate ischemic risk—though neither factor alone was predictive.
This aligns with data in broader post-PCI populations, with or without AFib:
- Young-Hoon Jeong, MD, PhD’s team (European Heart Journal, 2024) in South Korea showed that patients with combined platelet-fibrin clot strength and high platelet reactivity had the highest risk for MACE post-PCI (more than patients with either factor alone).
- A 2023 study from Fudan University in China reported similar results, where “a combination of high fibrinogen and HRPR may identify recurrent adverse ischemic events over 12 months.”
It’s encouraging to see continued momentum toward individualized post-intervention strategies, especially in tailoring OAC and antiplatelet therapy.
References:
Read the full article here.
Article: Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention
Authors: Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B Olivier
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals